Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation

P. Tsirigotis, I. Danylesko, K. Gkirkas, N. Shem-Tov, R. Yerushalmi, M. Stamouli, A. Avigdor, A. Spyridonidis, J. Gauthier, G. Goldstein, J. Apostolidis, M. Mohty, A. Shimoni, A. Nagler

Research output: Contribution to journalArticlepeer-review

Abstract

In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.

Original languageEnglish
Pages (from-to)1313-1317
Number of pages5
JournalBone Marrow Transplantation
Volume51
Issue number10
DOIs
StatePublished - 1 Oct 2016
Externally publishedYes

Fingerprint

Dive into the research topics of 'Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this